Announcement of Financial Results
BrainsWay Ltd. (NASDAQ: BWAY), a pioneering company in noninvasive neurostimulation treatments, is preparing to unveil its second quarter financial results for 2025. With a focus on enhancing mental health therapies, the company will share this pivotal information before the U.S. markets open. This disclosure marks a significant time for both investors and those interested in the advancements made in the field of mental health treatment.
What to Expect During the Conference Call
On the date of the announcement, BrainsWay will host a conference call at 8:30 AM Eastern Time. This call represents an opportunity for the management team to discuss the financial outcomes and operational highlights from the previous quarter. Participants can anticipate insights into business performance and future initiatives that underscore BrainsWay's commitment to addressing mental health disorders.
How to Join the Call
For those interested in participating, the conference can be accessed through several dial-in numbers for both U.S. and international callers. U.S.-based participants can dial 1-877-300-8521, while international attendees may use 1-412-317-6026. Specifically in Israel, the number is 1-80-921-2373. Attendees should note that the Conference ID is 10201287 for reference.
Exploring BrainsWay's Technology
BrainsWay has emerged as a prominent name in the field of neurostimulation with its revolutionary Deep Transcranial Magnetic Stimulation technology. This ground-breaking approach targets mental health conditions like major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The company is recognized for being the first in its field to receive FDA clearance for multiple treatment indications, backed by extensive clinical studies.
The Importance of Research and Development
The quest for improving mental health treatments remains at the core of BrainsWay’s mission. Ongoing clinical trials exploring additional psychiatric, neurological, and addiction disorders signify the company's dedication to advancing neuroscience. Each trial adds to the comprehensive clinical library that supports the efficacy of their Deep TMS platform, showcasing a commitment to research.
Looking Ahead: Future Initiatives
As BrainsWay's operations expand across the United States and into international markets, there is an increasing urgency to raise awareness about the benefits of Deep TMS. By improving access to their groundbreaking treatments, BrainsWay aims to transform lives facing mental health challenges. The upcoming financial results will likely include discussions on initiatives to broaden access to these innovative therapies.
Contact Information for Inquiries
For those seeking further details, BrainsWay encourages inquiries to be directed to their Chief Financial Officer, Ido Marom. Individuals can reach Ido directly via email at Ido.Marom@BrainsWay.com. Additionally, for investor-related queries, Brian Ritchie from LifeSci Advisors is available at britchie@lifesciadvisors.com for comprehensive support.
Frequently Asked Questions
When will BrainsWay announce its financial results?
BrainsWay is set to report its financial results before the market opens on a designated Wednesday in August 2025.
How can I participate in the conference call?
You can join the call using the respective dial-in numbers provided for U.S. and international callers, along with the Conference ID.
What groundbreaking technology does BrainsWay offer?
The company is known for its Deep Transcranial Magnetic Stimulation technology, designed to treat various mental health disorders.
Who can I contact for more information?
Ido Marom, the Chief Financial Officer, is available for queries at Ido.Marom@BrainsWay.com.
What are the implications of the upcoming financial results?
The results will provide insights into BrainsWay's performance and future strategies in advancing mental health treatments.
